| __timestamp | Cytokinetics, Incorporated | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17268000 | 504755000 |
| Thursday, January 1, 2015 | 19667000 | 838526000 |
| Friday, January 1, 2016 | 27823000 | 1177697000 |
| Sunday, January 1, 2017 | 36468000 | 1320433000 |
| Monday, January 1, 2018 | 31282000 | 1556200000 |
| Tuesday, January 1, 2019 | 39610000 | 1834800000 |
| Wednesday, January 1, 2020 | 52820000 | 1346000000 |
| Friday, January 1, 2021 | 96803000 | 1824900000 |
| Saturday, January 1, 2022 | 177977000 | 2115900000 |
| Sunday, January 1, 2023 | 173612000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Data in motion
In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Regeneron Pharmaceuticals, Inc. and Cytokinetics, Incorporated, from 2014 to 2023. Over this period, Regeneron consistently outpaced Cytokinetics in SG&A spending, reflecting its expansive operations and market reach. Notably, Regeneron's SG&A expenses surged by approximately 420% from 2014 to 2023, peaking at $2.63 billion. In contrast, Cytokinetics exhibited a more modest increase of around 900%, reaching $173 million in 2023. This disparity underscores the differing scales and strategic priorities of these companies. As the biotech sector continues to evolve, understanding these financial dynamics offers valuable insights into the operational strategies that drive success.
Pfizer Inc. or Regeneron Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Vertex Pharmaceuticals Incorporated and Cytokinetics, Incorporated: SG&A Spending Patterns Compared
Regeneron Pharmaceuticals, Inc. or Viatris Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Exelixis, Inc.
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG Trends and Insights
Regeneron Pharmaceuticals, Inc. or Ligand Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. and Galapagos NV: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Novavax, Inc.
BioMarin Pharmaceutical Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and BioCryst Pharmaceuticals, Inc.